RA
HZNP

Ramius Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ramius Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-141,528
Closed -$15.4M – 73
2023
Q1 		$15.4M Buy
+141,528
New +$15.6M 16.22% 1

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ramius Advisors's HZNP Position: Q2 2023 in Review

Ramius Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 141,528 shares — an estimated $15.4M sold.

Ramius Advisors first reported a position in HZNP in Q1 2023 and held it in 1 quarter. The position peaked at $15.4M in Q1 2023. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

  • Ramius Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Ramius Advisors sold 141,528 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $15.4M.
  • Ramius Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 1 quarter.
  • Ramius Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $15.4M in Q1 2023.
  • 519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Ramius Advisors's 13F filing for Q2 2023.